Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value

Frontiers in Cardiovascular Medicine

Yang Wu¹  Jie Cui¹  Jinjin Lu¹  Zongjing Fan¹  Dong Li¹  Liandi Xie¹  Xiaoyun Cui¹  Yan Li¹  Qian Lin²  Xingxing Li³ 

[1] Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China;Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China;Second Clinical School of Medicine, Beijing University of Chinese Medicine, Beijing, China;

关键词: heart failure;    trimethylamine N-oxide;    major adverse cardiovascular events;    all-cause mortality;    meta-analysis;   

DOI  :  10.3389/fcvm.2022.817396

来源: DOAJ

【 摘 要 】

ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208

【 授权许可】

Unknown